DOI QR코드

DOI QR Code

Protective Effect of Right Ventricular Mitochondrial Damage by Cyclosporine A in Monocrotaline-induced Pulmonary Hypertension

  • Lee, Dong Seok (Department of Pediatrics, Dongguk University School of Medicine) ;
  • Jung, Yong Wook (Department of Anatomy, Dongguk University School of Medicine)
  • 투고 : 2018.02.19
  • 심사 : 2018.06.05
  • 발행 : 2018.12.31

초록

Background and Objectives: Mitochondria play a key role in the pathophysiology of heart failure and mitochondrial permeability transition pore (MPTP) play a critical role in cell death and a critical target for cardioprotection. The aim of this study was to evaluate the protective effects of cyclosporine A (CsA), one of MPTP blockers, and morphological changes of mitochondria and MPTP related proteins in monocrotaline (MCT) induced pulmonary arterial hypertension (PAH). Methods: Eight weeks old Sprague-Dawley rats were randomized to control, MCT (60 mg/kg) and MCT plus CsA (10 mg/kg/day) treatment groups. Four weeks later, right ventricular hypertrophy (RVH) and morphological changes of right ventricle (RV) were done. Western blot and reverse transcription polymerase chain reaction (RT-PCR) for MPTP related protein were performed. Results: In electron microscopy, CsA treatment prevented MCT-induced mitochondrial disruption of RV. RVH was significantly increased in MCT group compared to that of the controls but RVH was more increased with CsA treatment. Thickened medial wall thickness of pulmonary arteriole in PAH was not changed after CsA treatment. In western blot, caspase-3 was significantly increased in MCT group, and was attenuated in CsA treatment. There were no significant differences in voltage-dependent anion channel, adenine nucleotide translocator 1 and cyclophilin D expression in western blot and RT-PCR between the 3 groups. Conclusions: CsA reduces MCT induced RV mitochondrial damage. Although, MPTP blocking does not reverse pulmonary pathology, it may reduce RV dysfunction in PAH. The results suggest that it could serve as an adjunctive therapy to PAH treatment.

키워드

과제정보

연구 과제 주관 기관 : Dongguk University

참고문헌

  1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S. https://doi.org/10.1016/j.jacc.2004.02.029
  2. Martin KB, Klinger JR, Rounds SI. Pulmonary arterial hypertension: new insights and new hope. Respirology 2006;11:6-17. https://doi.org/10.1111/j.1440-1843.2006.00778.x
  3. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005;258:199-215. https://doi.org/10.1111/j.1365-2796.2005.01542.x
  4. Rosca MG, Hoppel CL. Mitochondrial dysfunction in heart failure. Heart Fail Rev 2013;18:607-22. https://doi.org/10.1007/s10741-012-9340-0
  5. Kwong JQ, Molkentin JD. Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. Cell Metab 2015;21:206-14. https://doi.org/10.1016/j.cmet.2014.12.001
  6. Haworth RA, Hunter DR. The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys 1979;195:460-7. https://doi.org/10.1016/0003-9861(79)90372-2
  7. Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 2009;46:821-31. https://doi.org/10.1016/j.yjmcc.2009.02.021
  8. Crompton M, Costi A. Kinetic evidence for a heart mitochondrial pore activated by Ca2+, inorganic phosphate and oxidative stress. A potential mechanism for mitochondrial dysfunction during cellular Ca2+ overload. Eur J Biochem 1988;178:489-501. https://doi.org/10.1111/j.1432-1033.1988.tb14475.x
  9. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-8. https://doi.org/10.1042/bj3070093
  10. Sheu JJ, Chua S, Sun CK, et al. Intra-coronary administration of cyclosporine limits infarct size, attenuates remodeling and preserves left ventricular function in porcine acute anterior infarction. Int J Cardiol 2011;147:79-87. https://doi.org/10.1016/j.ijcard.2009.08.008
  11. Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 2012;165:1235-45. https://doi.org/10.1111/j.1476-5381.2011.01700.x
  12. Lim SY, Hausenloy DJ, Arjun S, et al. Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. J Cell Mol Med 2011;15:2443-51. https://doi.org/10.1111/j.1582-4934.2010.01235.x
  13. Bach PH, Lock EA. Nephrotoxicity: In Vitro and in Vivo, Animals to Man. 1st ed. New York (NY): Springer Science and Business Media; 2013. p.707.
  14. Voelkel NF, Natarajan R, Drake JI, Bogaard HJ. Right ventricle in pulmonary hypertension. Compr Physiol 2011;1:525-40.
  15. Daicho T, Yagi T, Abe Y, et al. Possible involvement of mitochondrial energy-producing ability in the development of right ventricular failure in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Sci 2009;111:33-43. https://doi.org/10.1254/jphs.08322FP
  16. Hong YM, Kwon JH, Choi S, Kim KC. Apoptosis and inflammation associated gene expressions in monocrotaline-induced pulmonary hypertensive rats after bosentan treatment. Korean Circ J 2014;44:97-104. https://doi.org/10.4070/kcj.2014.44.2.97
  17. Campian ME, Verberne HJ, Hardziyenka M, et al. Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats. J Nucl Med 2009;50:1371-7. https://doi.org/10.2967/jnumed.108.061366
  18. Zuo XR, Wang Q, Cao Q, et al. Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulmonary arterial hypertension. PLoS One 2012;7:e44485. https://doi.org/10.1371/journal.pone.0044485
  19. Zungu-Edmondson M, Shults NV, Wong CM, Suzuki YJ. Modulators of right ventricular apoptosis and contractility in a rat model of pulmonary hypertension. Cardiovasc Res 2016;110:30-9. https://doi.org/10.1093/cvr/cvw014
  20. Kinnally KW, Peixoto PM, Ryu SY, Dejean LM. Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim Biophys Acta 2011;1813:616-22. https://doi.org/10.1016/j.bbamcr.2010.09.013
  21. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004;23:2785-96. https://doi.org/10.1038/sj.onc.1207517
  22. Halestrap AP, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol 2015;78:129-41. https://doi.org/10.1016/j.yjmcc.2014.08.018
  23. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005;434:658-62. https://doi.org/10.1038/nature03434
  24. Ramachandran A, Lebofsky M, Baines CP, Lemasters JJ, Jaeschke H. Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury. Free Radic Res 2011;45:156-64. https://doi.org/10.3109/10715762.2010.520319
  25. Lim WY, Messow CM, Berry C. Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis. Br J Pharmacol 2012;165:2034-43. https://doi.org/10.1111/j.1476-5381.2011.01691.x
  26. Gomez L, Li B, Mewton N, et al. Inhibition of mitochondrial permeability transition pore opening: translation to patients. Cardiovasc Res 2009;83:226-33. https://doi.org/10.1093/cvr/cvp063
  27. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-81. https://doi.org/10.1056/NEJMoa071142
  28. Ghaffari S, Kazemi B, Toluey M, Sepehrvand N. The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. Cardiovasc Ther 2013;31:e34-9. https://doi.org/10.1111/1755-5922.12010

피인용 문헌

  1. Resveratrol Prevents Right Ventricle Dysfunction, Calcium Mishandling, and Energetic Failure via SIRT3 Stimulation in Pulmonary Arterial Hypertension vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/9912434
  2. Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/9993060
  3. Mitochondrial Dysfunction and Permeability Transition in Neonatal Brain and Lung Injuries vol.10, pp.3, 2018, https://doi.org/10.3390/cells10030569